The immunoassay method has been improved by many researchers, and has became a mature method. Generally, only an antigen or an antibody in one assay medium is measured by the immunoassay. However, if we can determine many analytes by using an immunoassay in one assay medium, we can obtain many benefits, such as saving time, materials and labor. Trials of the simultaneous determination by immunoassay were carried out by time-resolved fluoroimmunoassay (TR-FIA). We can determine multiple substances with the simultaneous use of various rare earth ions e.g. Eu 3+ , Sm 3+ , Tb 3+ by TR-FIA. [1] [2] [3] Further, Xu et al. 4 reported on simultaneous quadruple TR-FIA. Antigens or antibodies were labeled with four kinds of rare earth ion (Eu 3+ , Sm 3+ , Tb 3+ and Dy 3+ ) chelate in the TR-FIA. Their method was very significant, but a particular enhancement solution was required for the assay of Tb 3+ and Dy 3+ . The method is less sensitive to Sm 3+ and Dy 3+ than the other ions. Also, we have reported on the simultaneous determination of two or three analytes by using TR-FIA. [5] [6] [7] Recently, we established a highly sensitive bioluminescent assay of acetate kinase (AK) and pyruvate phosphate dikinase (PPDK) using firefly luciferase and luciferin as a detection system. We succeeded in detecting 8.6 × 10 -21 mol/assay for AK and 1.4 × 10 -20 mol/assay for PPDK, respectively. These enzymes were applicable in bioluminescent an enzyme immunoassay (BL-EIA) for various biological samples. 8-13 AK and PPDK are enzymes that generate ATP, and react under similar conditions. We have now developed simultaneous bioluminescent assays using AK and PPDK. The principle of the proposed assay is shown in Fig. 1 . In the first step, AK generates ATP from ADP and acetylphosphate, and ATP is determined by the firefly luciferase-luciferin reaction. In the second step, the bioluminescent emission from AK is quenched by the addition of glucose and ADP-dependent hexokinase (ADP-HK) 14 We have developed a simultaneous bioluminescent measurement of acetate kinase (AK) and pyruvate phosphate dikinase (PPDK) activities and its application to a tandem enzyme immunoassay. The principle of the proposed assay is as follows. In the first step, AK generates ATP from ADP and acetylphosphate, and the ATP is determined by the firefly luciferase-luciferin reaction. In the second step, the bioluminescent intensity from AK is eliminated by adding glucose and ADP-dependent hexokinase, which forms AMP from ADP. At the same time, the PPDK catalyzes the interconversion of AMP, diphosphate, and phosphoenolpyruvate to ATP, phosphate and pyruvate. The ATP formed by PPDK is also determined by the firefly luciferase-luciferin reaction. The detection limits (at blank + 3SD) of AK and PPDK were 1.03 × 10 -20 and 2.05 × 10 -20 mol per assay, respectively. The method was applicable to a bioluminescent enzyme immunoassay for the assay of insulin and C-peptide in the same sample.
ATP, phosphate and pyruvate. The ATP from PPDK is also determined by the firefly luciferase-luciferin reaction. Furthermore, we selected insulin and C-peptide as analytes, and applied the proposed method to BL-EIA for the simultaneous measurement of these two analytes.
Materials and Methods

Reagents
PPDK (from Microbispora rosea subsp. Aerata, EC 2.7.9.1) and thermostable Thr 217 Ile mutant of Luciola cruciata firefly luciferase (EC 1.13.12.7) were obtained from Kikkoman Co. (Chiba, Japan). AK (from B. stearothermophilus, EC 2.7.2.1) was purchased from Seikagakukogyo Co. (Tokyo). ADP-HK (from Pyrococcus furiosus, EC 2.7.1.147) was donated from Asahi Chemical Industry Co., Ltd. (Shizuoka, Japan). D-Luciferin and Biotinamidocaproate N-hydroxysuccinimide ester (NHS-LC-biotin) were purchased from Sigma Chemical Co. (St. Louis, MO). N-Succinimidyl-6-maleimidohexanoate (EMCS), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) and fluorescein-4-isothiocyanate (FITC) were from Dojindo Laboratories (Kumamoto, Japan). Rabbit anti-FITC IgG and mouse monoclonal antibodies to C-peptide were obtained from DAKO Japan Co. (Kyoto, Japan). C-peptide was purchased from American Peptide Co., Inc. (Sunnyvale, CA). Insulin and mouse monoclonal antibodies to insulin were gifted from Tosoh Co. (Tokyo, Japan).
Simultaneous bioluminescent measurement for AK and PPDK activities
Each of 10 µl of standard AK and PPDK solutions was added to a microtiter plate. Then, 100 µl of a bioluminescent reagent for AK (containing 1.25 µmol/l ADP, 2.5 mmol/l acetylphosphate, 10 mmol/l MgSO4, 0.35 mmol/l luciferin and 0.77 g/l luciferase in 50 mM HEPES-KOH buffer, pH 7.0) was added and incubated for 15 min at 37˚C. The bioluminescent intensity of AK was integrated for 5 s by a MicroLumat LB96P luminescent reader (EG&G Berthold, Germany). Then, to the same wells of the microtiter plate were added 100 µl of a bioluminescent reagent for PPDK (containing 5 µmol/l AMP, 304 µmol/l PPi, 560 µmol/l PEP, 15 mmol/l MgSO4, 20 mmol/l glucose, 8.1 mU/ml ADP-HK, 0.35 mmol/l luciferin and 1 g/l luciferase in 50 mM HEPES-KOH buffer, pH 7.0), and reincubated for 20 min at 37˚C. The bioluminescent intensity of PPDK was integrated for 5 s.
Preparation of PPDK labeled rabbit anti-FITC Fab'
We prepared PPDK labeled rabbit anti-FITC Fab' according to a slightly modified method of Hashida et al. 15 Briefly, to introduce the maleimide group into PPDK, 2 mg of PPDK in 0.1 M phosphate buffered saline (pH 7.0) was reacted with 10 µl of an EMCS (0.08 mg) solution in DMSO. After incubation for 1 h, the excess EMCS derivatives were removed by gel chromatography using a Sephadex G-25 column (15 mm i.d. × 450 mm). The fractions of maleimide-PPDK were collected and concentrated by ultrafiltration. Then, 2 mg of the maleimide-PPDK was mixed with 0.87 mg of rabbit anti-FITC Fab', which was prepared from rabbit anti-FITC IgG digested by pepsin, and reduced by 2-mercaptoethylamine. The mixture was purified by HPLC gel chromatography using a TSK-gel G-3000SW column (21.5 mm i.d. × 300 mm). The fractions of PPDK labeled rabbit anti-FITC Fab' which have high immunoand enzyme-reactivity were added to a water-soluble gelatin solution as a stabilizer, and then stored at -20˚C prior to use.
Biotinylated acetatekinase-streptavidin complex solution
We already succeeded to use a biotinylated acetatekinase (b-AK)-streptavidin (SA) complex (AK-ABC) solution for detecting a biotinylated antibody or antigen bound on a microtiter plate. [10] [11] [12] The AK-ABC was useful to detect for biotinylated component as a universal reagent. Therefore, we used AK-ABC for this report.
AK was biotinylated by incubating 45 µl of a 22 µM AK solution in a 50 mM HEPES buffer (pH 7.0) by adding 5 µl of a 1.1 mM NHS-LC-biotin DMSO solution for 1 h at 25˚C. The excess biotin derivative was removed by passing the reaction mixture through a PD-10 column (Amersham Pharmacia Biotech, Uppsala, Sweden) equilibrated with 0.1 M HEPES buffer (pH 7.0). The b-AK solution was stored at -20˚C before use.
The AK-ABC solution was prepared according to our previous report. [10] [11] [12] Briefly, a b-AK (1.1 × 10 -9 mol/l) solution and an SA solution (2.2 × 10 -9 mol/l) were mixed with equivalent volumes and incubated for 30 min at room temperature. The AK-ABC was diluted (1:10) and then mixed with a PPDK labeled rabbit anti-FITC Fab' solution. One hundred microliters of the mixed solution were pipetted into the plate, which terminated the immunereaction.
Preparation of FITC-labeled mouse monoclonal anti-insulin IgG and biotinylated anti-C-peptide monoclonal antibody
We labeled mouse monoclonal anti-insulin IgG with FITC and anti-C-peptide monoclonal antibody with NHS-LC-biotin, respectively. The procedure of labeling for anti-insulin IgG with FITC was as described bellow. One milligram per ml of IgG in 50 mM sodium bicarbonate buffer (pH 9.5) was reacted with 50 µl of FITC (0.078 mg) solution in DMSO. After incubation at room temperature for 1 h, the reaction was stopped by adding 100 µl of 1 M Tris-HCl buffer (pH 7.0). The FITC-labeled IgG was purified on a Sephadex G-25 column (15 mm i.d. × 450 mm) equilibrated and eluted with 50 mM Tris-HCl buffer (pH 7.0) containing 0.9% NaCl and 0.05% NaN3. We collected 1 ml fractions of FITC-labeled IgG. The fractions with high immuno-reactivity were added to 10 µl of a 10% water-soluble gelatin solution and stored at -20˚C prior to use. For biotinylation of the antibody, we used 1 mg of an anti-C-peptide monoclonal antibody and 90.9 µg of NHS-LC-biotin instead of anti-insulin IgG and FITC.
Simultaneous sandwich BL-EIA for insulin and C-peptide
The wells of the microtiter plate were coated with a purified mouse anti-insulin and C-peptide monoclonal antibody. The wells were then post-coated by adding a 1% water-soluble gelatin solution containing 0.05% NaN3. The plates were stored at 4˚C prior to use. After washing the plate, 50 µl of a standard or sample solution, 50 µl of an FITC-labeled anti-insulin and biotinylated anti-C-peptide monoclonal antibody mixed solution were added to each well. The plates were incubated for 1 h at room temperature. After washing, 100 µl of PPDK labeled rabbit anti-FITC Fab' and a biotinylated AK-streptavidin complex mixed solution was added and allowed to stand for 1 h at room temperature. The microtiter plate was re-washed and assayed by the simultaneous bioluminescent detection method.
Results and Discussion
Simultaneous bioluminescent measurement of AK and PPDK activities
In the proposed assay, there was no interference in the measurement of the AK activity by PPDK. The sensitivity of AK was 1.03 × 10 -20 mol/assay (blank + 3SD, Fig. 2, left) , which is similar to the result of the individual assay. 10 In the second step, the PPDK assay was influenced by the bioluminescent intensity from AK. Therefore, ADP-HK and glucose were added to remove the bioluminescence of AK. To determine the optimum bioluminescent assay conditions for PPDK, various levels of ADP-HK and glucose in the bioluminescent reagent for PPDK were examined. We checked the background bioluminescence intensity in PPDK assay as an indicator (Fig. 3) . When ADP-HK and glucose were added more than 4.06 mU/ml and 4 mmol/l into bioluminescent reagent for PPDK, respectively, the background bioluminescences from various AK concentrations were low and stable. The excess ADP in the bioluminescent reagent for AK was eliminated by addition of 8.1 mU/ml of ADP-HK and 20 mmol/l of glucose into the bioluminescent reagent for PPDK. Therefore, a bioluminescent intensity due to PPDK could be obtained without any interference from AK.
As shown in Fig. 2 (right) , the calibration linearity of the PPDK assay ranged from 1.4 × 10 -19 to 4.5 × 10 -17 mol/assay. The intra-assay coefficients of variation (CV) for 8 replicates with each standard point of PPDK were from 1.6 to 5.7%. The detection limit (at blank + 3SD) was 2.05 × 10 -20 mol/assay. These results were similar to our previous report. The BL intensity from AK was stable at 37˚C for 30 min (Fig.  4) . In the second step, after the addition of a bioluminescent reagent for PPDK, the bioluminescence intensities from PPDK reached regularity for 20 min at 37˚C. After that, the bioluminescence intensities were stable for 30 min.
Simultaneous BL-EIA for insulin and C-peptide
The proposed simultaneous bioluminescent measurement for the AK and PPDK activities was applied to BL-EIA (Fig. 5) . We selected insulin and C-peptide, which are markers of diabetes, as representative analytes. In this BL-EIA, the labels for C-peptide and insulin were AK and PPDK, respectively. The characteristics of the BL-EIA were as follows. The measurable ranges of C-peptide and insulin were 0.03 -2.0 ng/ml and 0.63 -40.4 µU/ml (Fig. 6) , and the detection limits (at blank + 3SD) of C-peptide and insulin were 3.0 × 10 -16 and 9.9 × 10 -17 mol/assay. The intra-assay coefficients of variation of C-peptide and insulin with each standard point were 1.9 -6.7% (n = 8) and 2.9 -5.8% (n = 8), respectively.
The concentrations of insulin and C-peptide in plasma samples could be accurately measured by the BL-EIA. The values of C-peptide and insulin by the proposed BL-EIA were compared with a fluorescent enzyme immunoassay (EIA, Tosoh Co., Tokyo). These measurements were carried out in the Clinical Laboratory, Showa University Hospital. The regression equations determined for the results were y (BL-EIA) = 1.093x (EIA) -0.205 (n = 42, r = 0.922) for C-peptide and y (BL-EIA) = 0.957x (EIA) -7.873 (n = 28, r = 0.948) for insulin, respectively. A high degree of correlation was observed between the values obtained using the BL-EIA and those by the conventional methods. 
